ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Hit-to-Lead (H2L) in Drug Discovery Market Outlook, In‑Depth Analysis & Forecast to 2031
Published Date: November 2025
|
Report Code: QYRE-Auto-30M16704
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Hit to Lead H2L in Drug Discovery Market Research Report 2024
BUY CHAPTERS

Global Hit-to-Lead (H2L) in Drug Discovery Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-30M16704
Report
November 2025
Pages:145
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Oncodesign Services
Jubilant Biosys
WuXi AppTec
DomaineX
Evotec AG
NorthEast Biolab
SciLifeLab
Sygnature Discovery
Creative-Biolabs
Bioduro-Sundia
Enzymlogic
Dalriada
Immunocure
Honarnejad

Hit-to-Lead (H2L) in Drug Discovery Market

The global Hit-to-Lead (H2L) in Drug Discovery market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
In drug discovery, Hit-to-Lead (H2L) is a critical phase that follows the identification of initial "hits" from high-throughput screening or other lead generation methods. The goal of the H2L stage is to optimize these hit compounds to become more promising lead candidates for further development.
From a downstream perspective, Biopharmaceutical Companies accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Hit-to-Lead (H2L) in Drug Discovery leading manufacturers including Oncodesign Services, Enzymlogic, Dalriada, Immunocure, Jubilant Biosys, Wuxi AppTec, Domainex, Evotec, NorthEast BioLab, SciLifeLab, etc., dominate supply; the top five capture approximately % of global revenue, with Oncodesign Services leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Hit-to-Lead (H2L) in Drug Discovery market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation

Scope of Hit-to-Lead (H2L) in Drug Discovery Market Report

Report Metric Details
Report Name Hit-to-Lead (H2L) in Drug Discovery Market
Segment by Type
  • Small Molecules
  • Biologics
Segment by Application
  • Biopharmaceutical Companies
  • Government and Academic Institutes
  • Others
Sales by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Oncodesign Services, Enzymlogic, Dalriada, Immunocure, Jubilant Biosys, Wuxi AppTec, Domainex, Evotec, NorthEast BioLab, SciLifeLab, Honarnejad, Sygnature Discovery, Creative Biolabs, Bioduro-Sundia
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the Hit-to-Lead (H2L) in Drug Discovery study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
  • Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
  • Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
  • Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
  • Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
  • Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
  • Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
  • Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
  • Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
  • Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
  • Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
  • Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
  • Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 14: Actionable conclusions and strategic recommendations.
  • Why This Report:
  • Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
  • Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
  • Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
  • Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
  • Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
  • Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Hit-to-Lead (H2L) in Drug Discovery Market report?

Ans: The main players in the Hit-to-Lead (H2L) in Drug Discovery Market are Oncodesign Services, Enzymlogic, Dalriada, Immunocure, Jubilant Biosys, Wuxi AppTec, Domainex, Evotec, NorthEast BioLab, SciLifeLab, Honarnejad, Sygnature Discovery, Creative Biolabs, Bioduro-Sundia

What are the Application segmentation covered in the Hit-to-Lead (H2L) in Drug Discovery Market report?

Ans: The Applications covered in the Hit-to-Lead (H2L) in Drug Discovery Market report are Biopharmaceutical Companies, Government and Academic Institutes, Others

What are the Type segmentation covered in the Hit-to-Lead (H2L) in Drug Discovery Market report?

Ans: The Types covered in the Hit-to-Lead (H2L) in Drug Discovery Market report are Small Molecules, Biologics

1 Study Coverage
1.1 Introduction to Hit-to-Lead (H2L) in Drug Discovery: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Hit-to-Lead (H2L) in Drug Discovery Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Small Molecules
1.2.3 Biologics
1.3 Market Segmentation by Application
1.3.1 Global Hit-to-Lead (H2L) in Drug Discovery Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Biopharmaceutical Companies
1.3.3 Government and Academic Institutes
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Hit-to-Lead (H2L) in Drug Discovery Revenue Estimates and Forecasts 2020-2031
2.2 Global Hit-to-Lead (H2L) in Drug Discovery Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Hit-to-Lead (H2L) in Drug Discovery Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Hit-to-Lead (H2L) in Drug Discovery Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Small Molecules Market Size by Players
3.3.2 Biologics Market Size by Players
3.4 Global Hit-to-Lead (H2L) in Drug Discovery Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Hit-to-Lead (H2L) in Drug Discovery Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Hit-to-Lead (H2L) in Drug Discovery Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Hit-to-Lead (H2L) in Drug Discovery Market Size by Type (2020-2031)
6.4 North America Hit-to-Lead (H2L) in Drug Discovery Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Hit-to-Lead (H2L) in Drug Discovery Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Hit-to-Lead (H2L) in Drug Discovery Market Size by Type (2020-2031)
7.4 Europe Hit-to-Lead (H2L) in Drug Discovery Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Hit-to-Lead (H2L) in Drug Discovery Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Hit-to-Lead (H2L) in Drug Discovery Market Size by Type (2020-2031)
8.4 Asia-Pacific Hit-to-Lead (H2L) in Drug Discovery Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Hit-to-Lead (H2L) in Drug Discovery Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Hit-to-Lead (H2L) in Drug Discovery Market Size by Type (2020-2031)
9.4 Central and South America Hit-to-Lead (H2L) in Drug Discovery Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Hit-to-Lead (H2L) in Drug Discovery Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Hit-to-Lead (H2L) in Drug Discovery Market Size by Type (2020-2031)
10.4 Middle East and Africa Hit-to-Lead (H2L) in Drug Discovery Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Hit-to-Lead (H2L) in Drug Discovery Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Oncodesign Services
11.1.1 Oncodesign Services Corporation Information
11.1.2 Oncodesign Services Business Overview
11.1.3 Oncodesign Services Hit-to-Lead (H2L) in Drug Discovery Product Features and Attributes
11.1.4 Oncodesign Services Hit-to-Lead (H2L) in Drug Discovery Revenue and Gross Margin (2020-2025)
11.1.5 Oncodesign Services Hit-to-Lead (H2L) in Drug Discovery Revenue by Product in 2024
11.1.6 Oncodesign Services Hit-to-Lead (H2L) in Drug Discovery Revenue by Application in 2024
11.1.7 Oncodesign Services Hit-to-Lead (H2L) in Drug Discovery Revenue by Geographic Area in 2024
11.1.8 Oncodesign Services Hit-to-Lead (H2L) in Drug Discovery SWOT Analysis
11.1.9 Oncodesign Services Recent Developments
11.2 Enzymlogic
11.2.1 Enzymlogic Corporation Information
11.2.2 Enzymlogic Business Overview
11.2.3 Enzymlogic Hit-to-Lead (H2L) in Drug Discovery Product Features and Attributes
11.2.4 Enzymlogic Hit-to-Lead (H2L) in Drug Discovery Revenue and Gross Margin (2020-2025)
11.2.5 Enzymlogic Hit-to-Lead (H2L) in Drug Discovery Revenue by Product in 2024
11.2.6 Enzymlogic Hit-to-Lead (H2L) in Drug Discovery Revenue by Application in 2024
11.2.7 Enzymlogic Hit-to-Lead (H2L) in Drug Discovery Revenue by Geographic Area in 2024
11.2.8 Enzymlogic Hit-to-Lead (H2L) in Drug Discovery SWOT Analysis
11.2.9 Enzymlogic Recent Developments
11.3 Dalriada
11.3.1 Dalriada Corporation Information
11.3.2 Dalriada Business Overview
11.3.3 Dalriada Hit-to-Lead (H2L) in Drug Discovery Product Features and Attributes
11.3.4 Dalriada Hit-to-Lead (H2L) in Drug Discovery Revenue and Gross Margin (2020-2025)
11.3.5 Dalriada Hit-to-Lead (H2L) in Drug Discovery Revenue by Product in 2024
11.3.6 Dalriada Hit-to-Lead (H2L) in Drug Discovery Revenue by Application in 2024
11.3.7 Dalriada Hit-to-Lead (H2L) in Drug Discovery Revenue by Geographic Area in 2024
11.3.8 Dalriada Hit-to-Lead (H2L) in Drug Discovery SWOT Analysis
11.3.9 Dalriada Recent Developments
11.4 Immunocure
11.4.1 Immunocure Corporation Information
11.4.2 Immunocure Business Overview
11.4.3 Immunocure Hit-to-Lead (H2L) in Drug Discovery Product Features and Attributes
11.4.4 Immunocure Hit-to-Lead (H2L) in Drug Discovery Revenue and Gross Margin (2020-2025)
11.4.5 Immunocure Hit-to-Lead (H2L) in Drug Discovery Revenue by Product in 2024
11.4.6 Immunocure Hit-to-Lead (H2L) in Drug Discovery Revenue by Application in 2024
11.4.7 Immunocure Hit-to-Lead (H2L) in Drug Discovery Revenue by Geographic Area in 2024
11.4.8 Immunocure Hit-to-Lead (H2L) in Drug Discovery SWOT Analysis
11.4.9 Immunocure Recent Developments
11.5 Jubilant Biosys
11.5.1 Jubilant Biosys Corporation Information
11.5.2 Jubilant Biosys Business Overview
11.5.3 Jubilant Biosys Hit-to-Lead (H2L) in Drug Discovery Product Features and Attributes
11.5.4 Jubilant Biosys Hit-to-Lead (H2L) in Drug Discovery Revenue and Gross Margin (2020-2025)
11.5.5 Jubilant Biosys Hit-to-Lead (H2L) in Drug Discovery Revenue by Product in 2024
11.5.6 Jubilant Biosys Hit-to-Lead (H2L) in Drug Discovery Revenue by Application in 2024
11.5.7 Jubilant Biosys Hit-to-Lead (H2L) in Drug Discovery Revenue by Geographic Area in 2024
11.5.8 Jubilant Biosys Hit-to-Lead (H2L) in Drug Discovery SWOT Analysis
11.5.9 Jubilant Biosys Recent Developments
11.6 Wuxi AppTec
11.6.1 Wuxi AppTec Corporation Information
11.6.2 Wuxi AppTec Business Overview
11.6.3 Wuxi AppTec Hit-to-Lead (H2L) in Drug Discovery Product Features and Attributes
11.6.4 Wuxi AppTec Hit-to-Lead (H2L) in Drug Discovery Revenue and Gross Margin (2020-2025)
11.6.5 Wuxi AppTec Recent Developments
11.7 Domainex
11.7.1 Domainex Corporation Information
11.7.2 Domainex Business Overview
11.7.3 Domainex Hit-to-Lead (H2L) in Drug Discovery Product Features and Attributes
11.7.4 Domainex Hit-to-Lead (H2L) in Drug Discovery Revenue and Gross Margin (2020-2025)
11.7.5 Domainex Recent Developments
11.8 Evotec
11.8.1 Evotec Corporation Information
11.8.2 Evotec Business Overview
11.8.3 Evotec Hit-to-Lead (H2L) in Drug Discovery Product Features and Attributes
11.8.4 Evotec Hit-to-Lead (H2L) in Drug Discovery Revenue and Gross Margin (2020-2025)
11.8.5 Evotec Recent Developments
11.9 NorthEast BioLab
11.9.1 NorthEast BioLab Corporation Information
11.9.2 NorthEast BioLab Business Overview
11.9.3 NorthEast BioLab Hit-to-Lead (H2L) in Drug Discovery Product Features and Attributes
11.9.4 NorthEast BioLab Hit-to-Lead (H2L) in Drug Discovery Revenue and Gross Margin (2020-2025)
11.9.5 NorthEast BioLab Recent Developments
11.10 SciLifeLab
11.10.1 SciLifeLab Corporation Information
11.10.2 SciLifeLab Business Overview
11.10.3 SciLifeLab Hit-to-Lead (H2L) in Drug Discovery Product Features and Attributes
11.10.4 SciLifeLab Hit-to-Lead (H2L) in Drug Discovery Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 Honarnejad
11.11.1 Honarnejad Corporation Information
11.11.2 Honarnejad Business Overview
11.11.3 Honarnejad Hit-to-Lead (H2L) in Drug Discovery Product Features and Attributes
11.11.4 Honarnejad Hit-to-Lead (H2L) in Drug Discovery Revenue and Gross Margin (2020-2025)
11.11.5 Honarnejad Recent Developments
11.12 Sygnature Discovery
11.12.1 Sygnature Discovery Corporation Information
11.12.2 Sygnature Discovery Business Overview
11.12.3 Sygnature Discovery Hit-to-Lead (H2L) in Drug Discovery Product Features and Attributes
11.12.4 Sygnature Discovery Hit-to-Lead (H2L) in Drug Discovery Revenue and Gross Margin (2020-2025)
11.12.5 Sygnature Discovery Recent Developments
11.13 Creative Biolabs
11.13.1 Creative Biolabs Corporation Information
11.13.2 Creative Biolabs Business Overview
11.13.3 Creative Biolabs Hit-to-Lead (H2L) in Drug Discovery Product Features and Attributes
11.13.4 Creative Biolabs Hit-to-Lead (H2L) in Drug Discovery Revenue and Gross Margin (2020-2025)
11.13.5 Creative Biolabs Recent Developments
11.14 Bioduro-Sundia
11.14.1 Bioduro-Sundia Corporation Information
11.14.2 Bioduro-Sundia Business Overview
11.14.3 Bioduro-Sundia Hit-to-Lead (H2L) in Drug Discovery Product Features and Attributes
11.14.4 Bioduro-Sundia Hit-to-Lead (H2L) in Drug Discovery Revenue and Gross Margin (2020-2025)
11.14.5 Bioduro-Sundia Recent Developments
12 Hit-to-Lead (H2L) in Drug DiscoveryIndustry Chain Analysis
12.1 Hit-to-Lead (H2L) in Drug Discovery Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Hit-to-Lead (H2L) in Drug Discovery Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Hit-to-Lead (H2L) in Drug Discovery Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
FEATURED COMPANIES
Oncodesign Services
Jubilant Biosys
WuXi AppTec
DomaineX
Evotec AG
NorthEast Biolab
SciLifeLab
Sygnature Discovery
Creative-Biolabs
Bioduro-Sundia
Enzymlogic
Dalriada
Immunocure
Honarnejad
List of Tables
 Table 1. Global Hit-to-Lead (H2L) in Drug Discovery Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global Hit-to-Lead (H2L) in Drug Discovery Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global Hit-to-Lead (H2L) in Drug Discovery Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global Hit-to-Lead (H2L) in Drug Discovery Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global Hit-to-Lead (H2L) in Drug Discovery Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 7. Global Hit-to-Lead (H2L) in Drug Discovery Revenue by Players (2020-2025) & (US$ Million)
 Table 8. Global Hit-to-Lead (H2L) in Drug Discovery Revenue Market Share by Players (2020-2025)
 Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 10. Global Hit-to-Lead (H2L) in Drug Discovery by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hit-to-Lead (H2L) in Drug Discovery as of 2024)
 Table 11. Global Hit-to-Lead (H2L) in Drug Discovery Average Gross Margin (%) by Player (2020 VS 2024)
 Table 12. Global Hit-to-Lead (H2L) in Drug Discovery Companies Headquarters
 Table 13. Global Hit-to-Lead (H2L) in Drug Discovery Market Concentration Ratio (CR5 and HHI)
 Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 16. Global Hit-to-Lead (H2L) in Drug Discovery Revenue by Type (2020-2025) & (US$ Million)
 Table 17. Global Hit-to-Lead (H2L) in Drug Discovery Revenue by Type (2026-2031) & (US$ Million)
 Table 18. Key Product Attributes and Differentiation
 Table 19. Global Hit-to-Lead (H2L) in Drug Discovery Revenue by Application (2020-2025) & (US$ Million)
 Table 20. Global Hit-to-Lead (H2L) in Drug Discovery Revenue by Application (2026-2031) & (US$ Million)
 Table 21. Hit-to-Lead (H2L) in Drug Discovery High-Growth Sectors Demand CAGR (2024-2031)
 Table 22. Top Customers by Region
 Table 23. Top Customers by Application
 Table 24. North America Hit-to-Lead (H2L) in Drug Discovery Growth Accelerators and Market Barriers
 Table 25. North America Hit-to-Lead (H2L) in Drug Discovery Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 26. Europe Hit-to-Lead (H2L) in Drug Discovery Growth Accelerators and Market Barriers
 Table 27. Europe Hit-to-Lead (H2L) in Drug Discovery Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 28. Asia-Pacific Hit-to-Lead (H2L) in Drug Discovery Growth Accelerators and Market Barriers
 Table 29. Asia-Pacific Hit-to-Lead (H2L) in Drug Discovery Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 30. Central and South America Hit-to-Lead (H2L) in Drug Discovery Investment Opportunities and Key Challenges
 Table 31. Central and South America Hit-to-Lead (H2L) in Drug Discovery Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 32. Middle East and Africa Hit-to-Lead (H2L) in Drug Discovery Investment Opportunities and Key Challenges
 Table 33. Middle East and Africa Hit-to-Lead (H2L) in Drug Discovery Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 34. Oncodesign Services Corporation Information
 Table 35. Oncodesign Services Description and Major Businesses
 Table 36. Oncodesign Services Product Features and Attributes
 Table 37. Oncodesign Services Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 38. Oncodesign Services Revenue Proportion by Product in 2024
 Table 39. Oncodesign Services Revenue Proportion by Application in 2024
 Table 40. Oncodesign Services Revenue Proportion by Geographic Area in 2024
 Table 41. Oncodesign Services Hit-to-Lead (H2L) in Drug Discovery SWOT Analysis
 Table 42. Oncodesign Services Recent Developments
 Table 43. Enzymlogic Corporation Information
 Table 44. Enzymlogic Description and Major Businesses
 Table 45. Enzymlogic Product Features and Attributes
 Table 46. Enzymlogic Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 47. Enzymlogic Revenue Proportion by Product in 2024
 Table 48. Enzymlogic Revenue Proportion by Application in 2024
 Table 49. Enzymlogic Revenue Proportion by Geographic Area in 2024
 Table 50. Enzymlogic Hit-to-Lead (H2L) in Drug Discovery SWOT Analysis
 Table 51. Enzymlogic Recent Developments
 Table 52. Dalriada Corporation Information
 Table 53. Dalriada Description and Major Businesses
 Table 54. Dalriada Product Features and Attributes
 Table 55. Dalriada Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 56. Dalriada Revenue Proportion by Product in 2024
 Table 57. Dalriada Revenue Proportion by Application in 2024
 Table 58. Dalriada Revenue Proportion by Geographic Area in 2024
 Table 59. Dalriada Hit-to-Lead (H2L) in Drug Discovery SWOT Analysis
 Table 60. Dalriada Recent Developments
 Table 61. Immunocure Corporation Information
 Table 62. Immunocure Description and Major Businesses
 Table 63. Immunocure Product Features and Attributes
 Table 64. Immunocure Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 65. Immunocure Revenue Proportion by Product in 2024
 Table 66. Immunocure Revenue Proportion by Application in 2024
 Table 67. Immunocure Revenue Proportion by Geographic Area in 2024
 Table 68. Immunocure Hit-to-Lead (H2L) in Drug Discovery SWOT Analysis
 Table 69. Immunocure Recent Developments
 Table 70. Jubilant Biosys Corporation Information
 Table 71. Jubilant Biosys Description and Major Businesses
 Table 72. Jubilant Biosys Product Features and Attributes
 Table 73. Jubilant Biosys Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 74. Jubilant Biosys Revenue Proportion by Product in 2024
 Table 75. Jubilant Biosys Revenue Proportion by Application in 2024
 Table 76. Jubilant Biosys Revenue Proportion by Geographic Area in 2024
 Table 77. Jubilant Biosys Hit-to-Lead (H2L) in Drug Discovery SWOT Analysis
 Table 78. Jubilant Biosys Recent Developments
 Table 79. Wuxi AppTec Corporation Information
 Table 80. Wuxi AppTec Description and Major Businesses
 Table 81. Wuxi AppTec Product Features and Attributes
 Table 82. Wuxi AppTec Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 83. Wuxi AppTec Recent Developments
 Table 84. Domainex Corporation Information
 Table 85. Domainex Description and Major Businesses
 Table 86. Domainex Product Features and Attributes
 Table 87. Domainex Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 88. Domainex Recent Developments
 Table 89. Evotec Corporation Information
 Table 90. Evotec Description and Major Businesses
 Table 91. Evotec Product Features and Attributes
 Table 92. Evotec Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 93. Evotec Recent Developments
 Table 94. NorthEast BioLab Corporation Information
 Table 95. NorthEast BioLab Description and Major Businesses
 Table 96. NorthEast BioLab Product Features and Attributes
 Table 97. NorthEast BioLab Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 98. NorthEast BioLab Recent Developments
 Table 99. SciLifeLab Corporation Information
 Table 100. SciLifeLab Description and Major Businesses
 Table 101. SciLifeLab Product Features and Attributes
 Table 102. SciLifeLab Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 103. SciLifeLab Recent Developments
 Table 104. Honarnejad Corporation Information
 Table 105. Honarnejad Description and Major Businesses
 Table 106. Honarnejad Product Features and Attributes
 Table 107. Honarnejad Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 108. Honarnejad Recent Developments
 Table 109. Sygnature Discovery Corporation Information
 Table 110. Sygnature Discovery Description and Major Businesses
 Table 111. Sygnature Discovery Product Features and Attributes
 Table 112. Sygnature Discovery Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 113. Sygnature Discovery Recent Developments
 Table 114. Creative Biolabs Corporation Information
 Table 115. Creative Biolabs Description and Major Businesses
 Table 116. Creative Biolabs Product Features and Attributes
 Table 117. Creative Biolabs Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 118. Creative Biolabs Recent Developments
 Table 119. Bioduro-Sundia Corporation Information
 Table 120. Bioduro-Sundia Description and Major Businesses
 Table 121. Bioduro-Sundia Product Features and Attributes
 Table 122. Bioduro-Sundia Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 123. Bioduro-Sundia Recent Developments
 Table 124. Raw Materials Key Suppliers
 Table 125. Distributors List
 Table 126. Market Trends and Market Evolution
 Table 127. Market Drivers and Opportunities
 Table 128. Market Challenges, Risks, and Restraints
 Table 129. Research Programs/Design for This Report
 Table 130. Key Data Information from Secondary Sources
 Table 131. Key Data Information from Primary Sources


List of Figures
 Figure 1. Hit-to-Lead (H2L) in Drug Discovery Product Picture
 Figure 2. Global Hit-to-Lead (H2L) in Drug Discovery Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. Small Molecules Product Picture
 Figure 4. Biologics Product Picture
 Figure 5. Global Hit-to-Lead (H2L) in Drug Discovery Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 6. Biopharmaceutical Companies
 Figure 7. Government and Academic Institutes
 Figure 8. Others
 Figure 9. Hit-to-Lead (H2L) in Drug Discovery Report Years Considered
 Figure 10. Global Hit-to-Lead (H2L) in Drug Discovery Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 11. Global Hit-to-Lead (H2L) in Drug Discovery Revenue (2020-2031) & (US$ Million)
 Figure 12. Global Hit-to-Lead (H2L) in Drug Discovery Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 13. Global Hit-to-Lead (H2L) in Drug Discovery Revenue Market Share by Region (2020-2031)
 Figure 14. Global Hit-to-Lead (H2L) in Drug Discovery Revenue Market Share Ranking (2024)
 Figure 15. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 16. Small Molecules Revenue Market Share by Player in 2024
 Figure 17. Biologics Revenue Market Share by Player in 2024
 Figure 18. Global Hit-to-Lead (H2L) in Drug Discovery Revenue Market Share by Type (2020-2031)
 Figure 19. Global Hit-to-Lead (H2L) in Drug Discovery Revenue Market Share by Application (2020-2031)
 Figure 20. North America Hit-to-Lead (H2L) in Drug Discovery Revenue YoY (2020-2031) & (US$ Million)
 Figure 21. North America Top 5 Players Hit-to-Lead (H2L) in Drug Discovery Revenue (US$ Million) in 2024
 Figure 22. North America Hit-to-Lead (H2L) in Drug Discovery Revenue (US$ Million) by Type (2020 - 2031)
 Figure 23. North America Hit-to-Lead (H2L) in Drug Discovery Revenue (US$ Million) by Application (2020-2031)
 Figure 24. US Hit-to-Lead (H2L) in Drug Discovery Revenue (2020-2031) & (US$ Million)
 Figure 25. Canada Hit-to-Lead (H2L) in Drug Discovery Revenue (2020-2031) & (US$ Million)
 Figure 26. Mexico Hit-to-Lead (H2L) in Drug Discovery Revenue (2020-2031) & (US$ Million)
 Figure 27. Europe Hit-to-Lead (H2L) in Drug Discovery Revenue YoY (2020-2031) & (US$ Million)
 Figure 28. Europe Top 5 Players Hit-to-Lead (H2L) in Drug Discovery Revenue (US$ Million) in 2024
 Figure 29. Europe Hit-to-Lead (H2L) in Drug Discovery Revenue (US$ Million) by Type (2020-2031)
 Figure 30. Europe Hit-to-Lead (H2L) in Drug Discovery Revenue (US$ Million) by Application (2020-2031)
 Figure 31. Germany Hit-to-Lead (H2L) in Drug Discovery Revenue (2020-2031) & (US$ Million)
 Figure 32. France Hit-to-Lead (H2L) in Drug Discovery Revenue (2020-2031) & (US$ Million)
 Figure 33. U.K. Hit-to-Lead (H2L) in Drug Discovery Revenue (2020-2031) & (US$ Million)
 Figure 34. Italy Hit-to-Lead (H2L) in Drug Discovery Revenue (2020-2031) & (US$ Million)
 Figure 35. Russia Hit-to-Lead (H2L) in Drug Discovery Revenue (2020-2031) & (US$ Million)
 Figure 36. Asia-Pacific Hit-to-Lead (H2L) in Drug Discovery Revenue YoY (2020-2031) & (US$ Million)
 Figure 37. Asia-Pacific Top 8 Players Hit-to-Lead (H2L) in Drug Discovery Revenue (US$ Million) in 2024
 Figure 38. Asia-Pacific Hit-to-Lead (H2L) in Drug Discovery Revenue (US$ Million) by Type (2020-2031)
 Figure 39. Asia-Pacific Hit-to-Lead (H2L) in Drug Discovery Revenue (US$ Million) by Application (2020-2031)
 Figure 40. Indonesia Hit-to-Lead (H2L) in Drug Discovery Revenue (2020-2031) & (US$ Million)
 Figure 41. Japan Hit-to-Lead (H2L) in Drug Discovery Revenue (2020-2031) & (US$ Million)
 Figure 42. South Korea Hit-to-Lead (H2L) in Drug Discovery Revenue (2020-2031) & (US$ Million)
 Figure 43. Australia Hit-to-Lead (H2L) in Drug Discovery Revenue (2020-2031) & (US$ Million)
 Figure 44. India Hit-to-Lead (H2L) in Drug Discovery Revenue (2020-2031) & (US$ Million)
 Figure 45. Indonesia Hit-to-Lead (H2L) in Drug Discovery Revenue (2020-2031) & (US$ Million)
 Figure 46. Vietnam Hit-to-Lead (H2L) in Drug Discovery Revenue (2020-2031) & (US$ Million)
 Figure 47. Malaysia Hit-to-Lead (H2L) in Drug Discovery Revenue (2020-2031) & (US$ Million)
 Figure 48. Philippines Hit-to-Lead (H2L) in Drug Discovery Revenue (2020-2031) & (US$ Million)
 Figure 49. Singapore Hit-to-Lead (H2L) in Drug Discovery Revenue (2020-2031) & (US$ Million)
 Figure 50. Central and South America Hit-to-Lead (H2L) in Drug Discovery Revenue YoY (2020-2031) & (US$ Million)
 Figure 51. Central and South America Top 5 Players Hit-to-Lead (H2L) in Drug Discovery Revenue (US$ Million) in 2024
 Figure 52. Central and South America Hit-to-Lead (H2L) in Drug Discovery Revenue (US$ Million) by Type (2020-2031)
 Figure 53. Central and South America Hit-to-Lead (H2L) in Drug Discovery Revenue (US$ Million) by Application (2020-2031)
 Figure 54. Brazil Hit-to-Lead (H2L) in Drug Discovery Revenue (2020-2025) & (US$ Million)
 Figure 55. Argentina Hit-to-Lead (H2L) in Drug Discovery Revenue (2020-2025) & (US$ Million)
 Figure 56. Middle East and Africa Hit-to-Lead (H2L) in Drug Discovery Revenue YoY (2020-2031) & (US$ Million)
 Figure 57. Middle East and Africa Top 5 Players Hit-to-Lead (H2L) in Drug Discovery Revenue (US$ Million) in 2024
 Figure 58. South America Hit-to-Lead (H2L) in Drug Discovery Revenue (US$ Million) by Type (2020-2031)
 Figure 59. Middle East and Africa Hit-to-Lead (H2L) in Drug Discovery Revenue (US$ Million) by Application (2020-2031)
 Figure 60. GCC Countries Hit-to-Lead (H2L) in Drug Discovery Revenue (2020-2025) & (US$ Million)
 Figure 61. Israel Hit-to-Lead (H2L) in Drug Discovery Revenue (2020-2025) & (US$ Million)
 Figure 62. Egypt Hit-to-Lead (H2L) in Drug Discovery Revenue (2020-2025) & (US$ Million)
 Figure 63. South Africa Hit-to-Lead (H2L) in Drug Discovery Revenue (2020-2025) & (US$ Million)
 Figure 64. Hit-to-Lead (H2L) in Drug Discovery Industry Chain Mapping
 Figure 65. Channels of Distribution (Direct Vs Distribution)
 Figure 66. Bottom-up and Top-down Approaches for This Report
 Figure 67. Data Triangulation
 Figure 68. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Seventh Sense AI

SIMILAR REPORTS

Drug Development Testing Services Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Quantitative Structure Activity Relationship QSAR Market Research Report 2024
Small Molecule Drug Discovery Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Beta 2 Microglobulin B2M Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Lead to Account Matching and Routing Software Market Research Report 2024
Global HIT Cell Market Research Report 2025
Global Pazopanib HCl Reagent Market Research Report 2024
Heparin Induced Thrombocytopenia HIT Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global High Throughput Screening Market Research Report 2024
Global High throughput Screening HTS Assay Market Research Report 2024
Global H MET NH2 Hydrochloride Market Research Report 2025
Global H2 Receptor Antagonist Market Research Report 2025
Global High Throughput Screening Services for Drug Discovery Market Research Report 2024
Global Targeted Drug for Blood Cancers Market Research Report 2024
Global Synthetic Lethality based Drugs and Targets Market Insights Forecast to 2030
Global Hit to Lead H2L Service Market Research Report 2024
Global Heterojunction Battery HIT Market Research Report 2024
AI driven Drug Discovery Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Small Molecule Targeted Cancer Therapy Market Research Report 2025
Global Tetraimidazole HCl Market Research Report 2024

RELATED REPORTS

Global Pharmacy Chatbot Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-10T20319
Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Inline Pharmaceutical Packaging Leak Detection System Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-6Q20319
Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Radiological Marker Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-35Z19949
Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Pharmaceutical Biomanufacturing Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-26E19785
Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions